Kornimate/medical-research-clean huggingface dataset:
a digital intervention for hiv prevention in black adolescent girls

Conditions: HIV; Risk Reduction Behavior

Summary: the purpose of this study is to develop and evaluate an innovative behavioral hiv prevention videogame intervention to bolster motivation and provide skill-building opportunities to improve black adolescent girls' ability to negotiate around risk including advocating for partner hiv/sexually transmitted infection (sti) testing, increasing their knowledge and awareness of hiv/stis, and for reducing sexual risk-taking behaviors.

this study will develop and evaluate a multiplayer videogame aimed at black adolescent girls with the intent of teaching the ability to negotiate around risk including advocating for partner hiv/sti testing, increasing their knowledge and awareness of hiv/stis, and for reducing sexual risk-taking behaviors. the intervention will be developed and delivered as a social, multiplayer videogame, a compelling context for black adolescent girls who constantly interact and seek counsel from their peers. to this end, the specific aims, focusing on black adolescent girls aged 14-18 years, are to: 1. (phase 1) translate the culturally and socially-tailored card game one night stan to a multiplayer videogame called investidate using game design and content experts and focus group input from 30 black adolescent girls. 2. (phase 2) conduct a pilot randomized controlled trial comparing the multiplayer videogame investidate (the new adaptation of the one night stan intervention) vs. an attention/control non-health-related multiplayer videogame with 80 participants collecting assessment data at baseline, one, and four months to: 1. determine the intervention's acceptability and feasibility by collecting quantitative and qualitative data on black adolescent girls' satisfaction and gameplay experience of the intervention. 2. determine the preliminary impact of the intervention on knowledge (information), intentions/attitudes (motivation), social norms, and behavioral skills as related to: i) hiv/sti testing and partner testing and ii) condom use, and iii) sexual risk behavior reduction, such as alcohol and drug use.

Eligibility criteria:
inclusion criteria: both phases (includes focus groups- phase 1) * black (race) * heterosexual * currently enrolled in high school pilot test (phase 2) * ability to participate in web-based videogame * willing to sit for at least 60 minutes (to play the game) * no hiv testing in the last 12 months * ability to provide assent or parental/guardian consent exclusion criteria: * failure to meet inclusion criteria

Keywords: black adolescent girls
efficacy evaluation of avance qq collagen for skin beautification

Conditions: Skin Condition; Liposomal Encapsulation

Summary: to assess avance qq collagen product on skin condition improvement


Eligibility criteria:
inclusion criteria: * healthy male or female adults, age above 18 years old; * the grade of crow's feet above 2 (han et al. sci rep 13, 18903 (2023)); * commitment not to use products having activity comparable with that of the product to be tested during the study period; * free of any dermatological or systemic disorder that would interfere with results. exclusion criteria: * subject with obvious skin surface damage; * subject who had oral or topical medication which may affect skin condition within 1 month; * subject who is a vegetarian or likely to be acutely allergic to the listed ingredients in the product; * female who is pregnant, nursing or planning to become pregnant during the course of the study; * received facial laser therapy, chemical peeling in the past 2 months.

Keywords: avance qq collagen double nutri
hrqol among patients amputated due to peripheral arterial disease

Conditions: Quality of Life; Amputation; Peripheral Arterial Disease; Prosthesis User

Summary: a prospective cohort study over the prosthetic use among patients amputated after vascular disease and the impact of their hrqol.


Eligibility criteria:
inclusion criteria: * patients amputated at femoral, knee or tibial level due to peripheral arterial disease exclusion criteria: * patients not able to provide informed consent * patients not able to verbally express their experience of the amputation. * patients that not speak swedish
investigation on the incidence and course of covid-19 in patients with prior, ongoing or de novo itp. evaluation of the impact of covid-19 pandemic on the management of itp

Conditions: Immune Thrombocytopenia; ITP; Covid19; ITP Secondary to Infection

Summary: multicenter retrospective and prospective observational study based on the collection of sequential anonymized data from principal italian itp centers, to describe the clinical course of itp patients becoming infected by sars-cov-2 and of covid-19 patients developing de novo itp.

multicenter retrospective and prospective observational study based on the collection - through pre-piloted electronic crfs - of sequential anonymized data from principal italian itp centers representative of national geographical distribution, to evaluate, during a 2-years study period, both the cumulative incidence covid-19 occurring in patients with prior or ongoing itp (covid-19 in itp) and the cumulative incidence of de novo itp manifesting during covid-19 (itp in covid-19). data will be collected to describe the clinical course of patients in the two groups. the enrolment period will last 24 months or terminate at the last day of 1-month-covid-19 free in italy, whichever comes first. each patient will be followed up to the first visit scheduled as per common center practice, including at least six months after hospital discharge or end of quarantine home confinement.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * confirmed diagnosed of itp (itp could be past, ongoing, persistent \>3 months, chronic \>12 months) in patients that are in regular follow-up (at least once a year) and who have been diagnosed with covid-19 * all patients who develop de novo itp from 1st january 2020 to the end of study after a diagnosis of covid-19 or during the first 6 months after covid-19 recovery * signed informed consent exclusion criteria: • all subjects not fitting inclusion criteria
ultrasonographic air bronchogram in pediatric cap

Conditions: Pneumonia; Pediatric Infectious Disorder

Summary: this study evaluates the prognostic role of the change of arborescent air bronchogram, a typical ultrasonographic finding of lung consolidation due to pneumonia, in the management of pediatric cap.

this is a single-center prospective study to evaluate the prognostic role of the change of arborescent air bronchogram, a typical ultrasonographic finding of lung consolidation due to pneumonia, in the management of cap in terms of: 1) impact on rate of uncomplicated respiratory infections \[rate of uncomplicated cap\], 2) relationship to the time of resolution of clinical signs \[time to resolution of fever\], 3) change of antibiotic therapy not guided by microbiological examinations and, 4) length of hospitalization. at admission, the pediatric will evaluate clinical signs of respiratory distress, request microbiologic tests (nasopharyngeal swab specimens and pneumococcal urinary antigen) to detect causative pathogens of cap, and laboratory tests (complete blood cell count, acute-phase reactants c-reactive protein). finally, all children will undergo chest radiography (cxr). if cxr should be performed before the admission to pediatric unit, the radiological exam will be not repeated. ultrasonographic evaluation will be performed by pulmonologists. the first examination will be performed within 12 hours from admission. the pulmonologists will be blind to clinical and radiological data. in order to characterize the lung consolidation, a grading system based on the presence and the features of air bronchogram \[static, dynamic, dynamic with areas of lung recruitment\] will be adopted. the operator will collect and store images and videos (10seconds), these findings will be reviewed by an expert clinician in chest us blind to other data. after 48h from the admission, all children will undergo follow-up laboratory tests and lung us. in case of clinical deterioration, children will undergo further ultrasonographic evaluations according pediatric indications. finally, all children will undergo lung us after 7 ± 2 days from discharge.

Eligibility criteria:
inclusion criteria: * suspected cap * age from 1 to 16 years old * admission to pediatric unit * radiographic evidence of lung consolidation * written informed consent from parents exclusion criteria: * gestational age \< 36 weeks * previous diagnosis of cystic fibrosis * congenital pulmonary disease. * refusal to participate.

Keywords: chest ultrasound pediatric community acquired pneumonia air bronchogram
the comparision of minimally-invasive and open pancreaticoduodenectomy for pancreatic cancer

Conditions: Pancreatic Carcinoma; Surgery

Summary: minimally invasive pancreaticoduodenectomy remains one of the most challenging abdominal procedures. safety and feasibility remain controversial when comparing minimally-invasive with open pancreaticoduodenectomy, especially for malignant tumors.the aim of this study was to compare minimally invasive and open pancreatoduodenectomy for short-term outcomes and long-term follow-up in a randomized trial.

this study is to compare the efficiency and safety between minimally invasive (including laparoscopic and robotic) and open pancreaticoduodenectomy for pancreatic cancer. we design a prospective randomized study. patients with malignant pancreatic tumor who underwent pancreatoduodenectomy are recruited to the study. after obtaining informed consent, eligible patients are randomly allocated to minimally-invasive or open group before the operation day. the outcomes evaluated were hospital stay, and blood loss, radicality of surgery, duration of operation and complication rate as well as disease free survival and overall survival.

Eligibility criteria:
inclusion criteria: * age: \>18yr, \<75yr * patients with pancreatic cancer or non-pancreatic cancers (biliary duct cancer or ampullary cancer) who underwent pancreatoduodenectomy * preoperative imaging assessment is resectable or borderline resectable exclusion criteria: * benign tumors of the head of pancreas * enhanced ct diagnosis revealed that the excess of smv was more than 180 degrees, or distant metastasis. * conversion to laparotomy because of intraoperative difficulty

Keywords: minimally-invasive pancreaticoduodenectomy open pancreaticoduodenectomy pancreatic cancer
effectiveness of robot-assisted upper extremity rehabilitation in children with cerebral palsy

Conditions: Cerebral Palsy; Upper Extremity Problem

Summary: the use of robotic rehabilitation, a treatment method for improving the motor functions of the upper extremities, is gradually increasing in children with cerebral palsy. the aim of this study is to investigate the effect of robot-assisted rehabilitation for the upper extremity on upper extremity functions, manual skills and quality of life in patients with unilateral or bilateral/triplegic spastic cerebral palsy and also to compare the effect of robot-assisted upper extremity rehabilitation compared to traditional rehabilitation methods.

in this study, it was planned to include 42 patients diagnosed with unilateral or bilateral/triplegic spastic cerebral palsy, aged 5-15 years, who were treated in the pediatric rehabilitation service of ankara city hospital physical therapy and rehabilitation hospital, and met the inclusion criteria. participants will be divided into two groups as study and control groups. in addition to the conventional rehabilitation program, the study group will be included in the robot-assisted upper extremity rehabilitation program, while the control group will be included in the conventional rehabilitation program only. conventional rehabilitation program will be applied 5 days a week, lasting 60 minutes. the robotic rehabilitation program (with the armeo spring pediatric robotic rehabilitation system) will be implemented 3 days a week for 30 minutes in addition to the conventional rehabilitation program. participants will receive a total of 4 weeks of treatment. assessments will be made before initiating treatment, at the end of treatment, and 3 months after initiation of treatment.

Eligibility criteria:
inclusion criteria: * being diagnosed with unilateral or bilateral/triplegic spastic cerebral palsy * be between the ages of 5-15 * levels i, ii and iii according to the manual ability classification system (macs) * have sufficient cognitive level, such as the ability to understand and follow simple instructions, and to perform desired tasks * the upper extremity dimensions are suitable for the robot * parents and patients aged ≥ 9 years have agreed to participate in the study exclusion criteria: * injection of antispasticity drugs (eg botox) into upper extremity muscles and/or upper extremity orthopedic surgery in the last 6 months * having musculoskeletal disorders and peripheral nervous system disorders that impair the ability to use the upper extremity robotic system * having severe muscle spasticity and/or contracture * having uncontrolled seizures and/or presence of visually induced seizures * having severe learning difficulties, behavioral problems, skin lesions, visual and/or hearing difficulties that may affect function and participation

Keywords: cerebral palsy robotic rehabilitation upper extremity
an observational study of roactemra/actemra (tocilizumab) in smoking versus non-smoking patients with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: this observational study will assess the efficacy and safety of roactemra/actemra (tocilizumab) in smoking versus non-smoking patients with rheumatoid arthritis. data from patients treated in routine clinical practice with intravenous roactemra/actemra will be collected for 12 months each.


Eligibility criteria:
inclusion criteria: * adult patients, \> 18 years of age * rheumatoid arthritis, defined as fulfilling at least 4 of 7 american college of rheumatology (acr) criteria * treatment with roactemra/actemra exclusion criteria: * participation in interventional clinical studies
effects of deepure(pu-erh tea extract) on glycemic control

Conditions: Glucose Metabolism Disorders

Summary: this is a randomized, controlled, cross-over study on the effects of consumption of deepure puerh tea extract (pte) on glucose tolerance and metabolic markers.

the study will involve consuming three different doses: 1 gram, 1.5 grams, and 2 grams, and will be given in warm water, with a bland meal. the effects on glucose and insulin after consumption will be evaluated.the subjects will be randomly assigned to one of four groups with different sequences.

Eligibility criteria:
inclusion criteria: * men and women; * aged 18-70 years; * bmi between 20-30; * fasting blood glucose at screening between 71-125 mg/dl. both inclusive. exclusion criteria: * taking dietary supplements judged to interfere with the effects of deepure on glucose metabolism (for example: cinnamon extract; chromium picolinate; mulberry extract; bitter melon extract, green tea extracts, black tea extracts, pu-erh tea); * participation in other clinical trials, involving an investigational product or lifestyle change, during the last month; * participation in another research study during this trial, involving an investigational product or lifestyle change; taking prescription medication known to affect glucose metabolism; * taking over-the-counter medication known to affect glucose metabolism; * drinking 3 or more cups of tea daily; * unwilling to abstain from drinking tea for 24 hours before clinic visits; (if a person drinks tea within 24 hours of a clinic visit, the person's visit will be re-scheduled); * consuming 2 or more drinks of alcohol per day; * unwilling to abstain from drinking alcohol for 10 hours before clinic visits; * diagnosed with diabetes type i; taking medication for diabetes type ii; * diagnosed with the thyroid disorder hashimoto's disease; * past major surgery to your stomach or intestines (minor surgery not a problem such as hernia repair, appendix removal, gallbladder removal); * currently taking cholesterol-lowering medication (for example: statins); * currently taking coumadin; * major trauma within the past 6 months; * major surgery within the past 6 months; * severe chronic infectious disease (such as hiv, chronic hepatitis); * active depression; * self-reported eating disorders; * history of drug abuse during past two years; * currently going through intense stressful events or life changes; * women of child-bearing potential: pregnant, breast-feeding, or trying to become pregnant; * women of child-bearing potential: not using effective contraception; * food allergies or sensitivities to tea.
umbilical cord blood mononuclear cells for hypoxic neurologic injury in infants with congenital diaphragmatic hernia (cdh)

Conditions: Congenital Diaphragmatic Hernia

Summary: the purpose of this study is to investigate the use of autologous umbilical cord blood (ucb) mononuclear cells to mitigate hypoxic neurologic injury among infants with high-risk congenital diaphragmatic hernia (cdh).


Eligibility criteria:
inclusion criteria: * diagnosis of cdh between 20 and 36 weeks estimated gestational age (ega) * only one of the following fetal criteria and one of the following postnatal criteria must be met for enrollment. fetal criteria: an ultrasound (us)-obtained observed to expected lung to head ratio (o/e lhr) less than or equal to 35% or 2) a fetal magnetic resonance imaging (fmri)- obtained observed to expected total fetal lung volume (o/e tflv) less than or equal to 35%. postnatal criteria: 1) cord blood gas (cbg) with potenital hydrogen (ph) \ 20 x 2 total hours (not necessarily consecutive) within the first 24 hours. exclusion criteria: * genetic/chromosomal abnormality: trisomy 21, trisomy 18, trisomy 13 or other, significant genetic abnormality. microdeletions or other mild genetic abnormalities are not considered exclusionary. * severe/major cardiac anomaly: coarctation of the aorta, combined atrial and ventricular septal defects, hypoplastic left heart syndrome, tetralogy of fallot, double outlet right ventricle, atrioventricular canal defects, or other hemodynamically significant defects. * moderate/severe neurologic / intracranial abnormality: grade iii or iv intraparenchymal hemorrhage, space occupying mass or lesion, or clinically significant traumatic lesion such as a subdural or epidural hemorrhage. * prematurity \<30 weeks estimated gestational age (ega): birth at 29 6/7 weeks or before * participation in an alternative prenatal intervention study: fetoscopic endotracheal occlusion (feto) * unwillingness / inability to return for follow-up evaluation and assessment

Keywords: cdh
uterine round ligament preservation vs resection in laparoscopic inguinal hernia repair in women：a multicenter,stratified randomized controlled trial

Conditions: Inguinal Hernia; Laparoscopic Surgery; Randomized Controlled Trial

Summary: this study aims to compare the clinical effects of uterine round ligament preservation versus resection in laparoscopic inguinal hernia repair in women.the primary outcomes included time required for patient surgery.the secondary outcomes included inguinal hernia recurrence,quality of life assessment,indicators of postoperative recovery,, et al.


Eligibility criteria:
inclusion criteria: * ►age : female patients over 18 years of age without a childbearing requirement * diagnosis and basis : female patients diagnosed with unilateral inguinal hernia. * agreed to participate in this study and signed the informed consent form. exclusion criteria: * ►combined with severe heart, liver, kidney and other diseases. * pregnant or lactating women. * those with surgical contraindications.
optimal administration of allopurinol in dialysis patients

Conditions: Gout; Renal Insufficiency

Summary: gout has a strong association with the metabolic syndrome, and it is often seen in patients with renal insufficiency. allopurinol is a medication intended to lower uric acid and therefore prevents gout attacks. its metabolism is mainly renal, and some evidence shows that it is also dialyzable. the hypothesis is that allopurinol would be more efficacious to lower uric acid if it was given after dialysis only. the investigators will then switch administration of allopurinol to bedtime for dialysis patients currently taking that medication.

gout has a strong association with the metabolic syndrome, and it is often seen in patients with renal insufficiency. a study has shown an incidence of fifteen percent of gout in the first five years spent in dialysis and it was associated with an increased mortality. allopurinol is a medication intended to lower uric acid and therefore prevents gout attacks. its metabolism is mainly renal, and some studies from the early 1960s demonstrated that it is also dialyzable. at the moment, we do not have strong evidence of the optimal dosage of allopurinol with modern techniques of dialysis. the hypothesis is that allopurinol would be more efficacious to lower uric acid if it was given after dialysis only. the investigators will then switch administration of allopurinol to bedtime for dialysis patients currently taking that medication. dosage of uric acid will be performed to assess the efficacy of the intervention.

Eligibility criteria:
inclusion criteria: * subjects who receive chronic treatments of hemodialysis at maisonneuve-rosemont hospital * subjects who take allopurinol for at least a month exclusion criteria: * subjects who have had an acute gout attack in the past month * subjects with tumor lysis syndrome * sujects who have a history of hypersensitivity reaction to allopurinol * subjects with hepatic insufficiency * women who are pregnant or planning to become pregnant in the next three months

Keywords: allopurinol renal dialysis